SpringWorks Therapeutics Says Deal Termination Between Co & GlaxoSmithKline Intellectual Property Development Effective 180 Days After Notice Receipt
Portfolio Pulse from Benzinga Newsdesk
SpringWorks Therapeutics announced the termination of a deal with GlaxoSmithKline Intellectual Property Development, which will be effective 180 days after the notice receipt, according to an SEC filing.
June 07, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
SpringWorks Therapeutics announced the termination of a deal with GlaxoSmithKline Intellectual Property Development, effective 180 days after notice receipt.
The termination of the deal could negatively impact SpringWorks Therapeutics' stock price in the short term due to potential uncertainties and loss of collaboration benefits.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
GlaxoSmithKline Intellectual Property Development's deal with SpringWorks Therapeutics is set to terminate in 180 days.
The termination of the deal is less likely to have a significant impact on GlaxoSmithKline's stock price due to its larger and more diversified portfolio.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50